NRX Pharmaceuticals
Open
$4.02
Prev. Close
$4.03
High
$4.02
Low
$3.96
Market Snapshot
$131.28M
-5.3
-2.41
29
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is headquartered in Wilmington, Delaware and currently employs 29 full-time employees. The company went IPO on 2017-11-20. The company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.
Recently from Cashu
Ketamine Revolutionizes Mental Health Treatment: NRX Pharmaceuticals Positioned for Growth
Shifting Perspectives: Ketamine's Promising Role in Mental Health Treatment Ketamine, traditionally known for its use as an anesthetic, is experiencing a significant transformation in its application…
NRX Pharmaceuticals and Ketamine: Transforming Approaches to Mental Health Treatment
Shifting Paradigms: Ketamine's Role in Mental Health Treatment NRX Pharmaceuticals stands at the forefront of a growing movement that highlights ketamine's transformative potential in mental health tr…
NRX Pharmaceuticals: Innovating Mental Health Solutions Amid Biopharmaceutical Challenges
NRX Pharmaceuticals: Navigating Challenges in the Biopharmaceutical Landscape NRX Pharmaceuticals is currently focusing on advancing its innovative therapeutic solutions, particularly in the context o…
NRX Pharmaceuticals: Innovating Treatments and Strategies in Competitive Biopharmaceutical Landscape
NRX Pharmaceuticals: Focus on Innovation and Market Strategy Amid Competitive Landscape NRX Pharmaceuticals, a player in the biopharmaceutical sector, continues to navigate the complexities of drug de…